Antimicrobial Drug–Selection Markers for Burkholderia pseudomallei and B. mallei by Schweizer, Herbert P. & Peacock, Sharon J.
Genetic research into the select agents Burkholderia 
pseudomallei and B. mallei is currently hampered by a 
paucity of approved antimicrobial drug–selection markers. 
The strict regulations imposed on researchers in the United 
States but not in other parts of the world lead to discrep-
ancies in practice, hinder distribution of genetically modi-
ﬁ  ed strains, and impede progress in the ﬁ  eld. Deliberation 
and decisions regarding alternative selection markers (an-
timicrobial and nonantimicrobial drugs) by the international 
community, regulatory authorities, and funding agencies are 
needed. 
A
ntimicrobial drug–selection markers are essential tools 
for the bacterial geneticist. Gene deletions created by 
the insertion of a region of DNA carrying an antimicrobial 
drug resistance cassette enable geneticists to select mutants 
by using bacterial agar into which the relevant drug has 
been incorporated. Choice of an antimicrobial drug–selec-
tion marker for a given bacterial species is based on several 
factors: natural bacterial resistance, markers already avail-
able that would work in the organism of interest, and the 
choice of antimicrobial drugs used to treat natural disease 
caused by the pathogen.
Select agents are biological agents and toxins that have 
the potential to pose a severe threat to human health, ani-
mal or plant health, or animal or plant products. A recent 
increase in the number of persons and agencies undertaking 
research on select agents adds complexity to the use of an-
timicrobial drug–selection markers. First, there are speciﬁ  c 
regulations relating to select agents. Second, few genetic 
tools are available for those select agent organisms that 
have received limited attention. Third, some species are 
naturally resistant to a range of antimicrobial drug groups, 
limiting the choice of drugs for patient care and the pos-
sible markers available for experimental studies.
Restricted Use of Drug-Selection 
Markers with Select Agents
In the United States, the acquisition, possession, and 
use of select agent bacteria are governed by the following 
Federal Register publications: 42 Code of Federal Regula-
tions (CFR) Parts 72 and 73 for pathogens listed by the 
Department of Health and Human Services (HHS) and 7 
CFR Part 331 and 9 CFR Part 121 for plant and animal 
pathogens listed by the United States Department of Ag-
riculture (USDA). Some of the agents, including Burk-
holderia pseudomallei and B. mallei, are on both the HHS 
and the USDA lists. Restrictions and regulations include 
the application of antimicrobial drug–selection markers for 
genetic manipulation of these bacteria. A person or entity 
may not conduct a restricted experiment with a select agent 
unless approved by the appropriate entities. Restricted ex-
periments pertaining to use of selection markers are deﬁ  ned 
in 42 CFR Part 73, §73.13, section (b)(1), and the National 
Institutes of Health (NIH) Recombinant DNA Guidelines 
(Section III-A-1-a) as follows: experiments utilizing re-
combinant DNA that involve the deliberate transfer of a 
drug resistance trait to microorganisms that are not known 
to acquire the trait naturally, if such acquisition could com-
promise the use of the drug to control disease agents in hu-
mans, veterinary medicine, or agriculture. The NIH Ofﬁ  ce 
of Biotechnology Activities is responsible for these guide-
lines. Issues concerning transfer of drug resistance traits to 
select agents are brought to the Intragovernmental Select 
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Agents and Toxins Technical Advisory Committee for as-
sessment. The ﬁ  nal decision is made by HHS, USDA, or 
both, depending on the agent.
Current policy is that persons or entities must apply 
for approval for use of even those drugs (antimicrobial and 
others) for which it has clearly been established that such 
use will not compromise their ability to control a particular 
disease agent in humans, veterinary medicine, or agricul-
ture. Even if approval for use of these markers is granted 
to a number of institutions or persons, such approval does 
not automatically mean that their use is unrestricted and, 
therefore, exempt from restrictions under this policy.
Special Considerations for B. pseudomallei 
and B. mallei
B. pseudomallei and B. mallei are 2 closely related se-
lect agents that cause melioidosis and glanders, respective-
ly. B. mallei causes natural glanders, a rare disease of equids 
(1), although it can also cause rare infections in humans (2). 
By contrast, the disease caused by B. pseudomallei, human 
melioidosis, is endemic to much of Southeast Asia, northern 
Australia, and other parts of the Tropics around the world 
(including Central America and South America) and causes 
thousands of cases each year (3,4). These 2 organisms are 
intrinsically resistant to many antimicrobial drugs, includ-
ing  ﬁ   rst-, second-, and third-generation cephalosporins; 
penicillins; and polymyxin B (3). B. pseudomallei is natu-
rally resistant to gentamicin, but B. mallei is susceptible be-
cause of deletion of the genes encoding the AmrAB-OprA 
efﬂ  ux pump (5). These 2 species are usually susceptible 
to ceftazidime, the carbapenems, amoxicillin-clavulanate, 
piperacillin-tazobactam, doxycycline, and trimethoprim-
sulfamethoxazole (TMP-SMX) (6). First-line treatment 
for acute human melioidosis is intravenous ceftazidime 
or a carbapenem for at least 10–14 days, followed by oral 
TMP-SMX with or without doxycycline for 12–20 weeks 
(3,6). For patients who cannot tolerate ﬁ  rst-line therapy or 
for whom this therapy is contraindicated (e.g., children and 
pregnant women), the choice of oral therapy is amoxicillin-
clavulanate. The choice of treatment for human glanders is 
uncertain because of the rarity of this disease, but clinical 
experts suggest that treatment should be the same as for 
B. pseudomallei. Acquired resistance to carbapenem drugs 
has not been reported, and the rate of acquired resistance 
to ceftazidime and amoxicillin-clavulanate is low (<0.2%) 
(6). Acquired resistance to doxycycline is 2% and to TMP-
SMX is geographically variable (2.5% in Australia com-
pared with 13%–16% in northeast Thailand) (6).
Approved Selection Markers for 
B. pseudomallei and B. mallei
The markers approved for use with B. pseudomallei 
and B. mallei in the United States are kanamycin, gentami-
cin, zeocin, and polymyxin B (for B. pseudomallei), and 
kanamycin, zeocin, and polymyxin B (for B. mallei). Be-
cause both species are naturally resistant to polymyxin B, 
this drug is therefore of little use for the genetic manipu-
lation of these bacteria. B. pseudomallei is almost always 
naturally resistant to gentamicin and other aminoglyco-
sides, although ≈1 in 1,000 isolates cultured from patients 
with cases of melioidosis at a large hospital in northeast 
Thailand, where >250 cases are seen each year, were found 
to be susceptible. B. mallei is naturally susceptible to gen-
tamicin, but this marker is prohibited for use with this spe-
cies because it could potentially be used to treat infection. 
However, gentamicin can be used as a marker in B. pseudo-
mallei if the strain used is naturally susceptible. During 
1990–2005, the Wellcome Unit in Thailand identiﬁ  ed 4 
such strains (708a, 2188a, 2188b, and 3799a) in 3 patients 
with melioidosis (7). One potential drawback is that these 
strains are poorly characterized. For example, whether 
these strains are representative of the bacterial population 
as a whole is not clear.
To answer this question, the Wellcome Unit undertook 
sequence typing and determined that strain 708a is sequence 
type (ST) 23, strains 2188a and 2188b are ST47, and strain 
3799a is ST154. Because all 3 STs have been previously 
identiﬁ   ed, and several gentamicin-resistant strains have 
been identiﬁ  ed for each of the 3 clones, the susceptible 
strains are not rare in population genetic terms. Recent un-
published observations from our laboratories indicate that 
the gentamicin susceptibility in strains 708a, 2188b, and 
3799 results from a deletion (708a) or lack of expression 
(2188b and 3799a) of the amrAB-oprA efﬂ  ux pump operon. 
These results suggest that 708a may be a natural candidate 
for genetic manipulation experiments that use gentamicin, 
spectinomycin, streptomycin (8), and nourseothricin (9), 
and validate the use of laboratory-constructed Δ(amrAB-
oprA) mutants in such experiments.
Kanamycin and zeocin can be used for genetic manip-
ulation of B. pseudomallei and B. mallei, especially when 
driven from constitutive promoters; but even then, high 
concentrations of antimicrobial drugs are required (10). 
The recent development of site-speciﬁ  c recombinase sys-
tems for use in Burkholderia spp. enables in vivo excision 
and recycling of selection markers, thus expanding the use 
of the few precious markers currently approved for genetic 
manipulation of these bacteria (10).
Approval has also been granted for testing of some 
nonantimicrobial drug–selection markers such as tellu-
rite and triclosan. Unpublished work from our laboratories 
showed that tellurite resistance conferred by kilA-telAB (11) 
may be a useful marker for B. pseudomallei (MIC ≈1 μg/mL) 
and B. mallei (MIC <0.5 μg/mL). Similarly, FabL-mediated 
triclosan resistance (12) may be useful in B. mallei (MIC = 5 
μg/mL) but not in B. pseudomallei (MIC >64 μg/mL).
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Restricted Selection Markers
Consideration of currently restricted selection markers 
highlights several possible candidates. Until relatively re-
cently, chloramphenicol was used in Thailand for the oral 
phase of melioidosis treatment, but this use ceased after a 
clinical trial showed it to be unnecessary (13). Rare excep-
tions to this exist, an example of which is a patient with neu-
rologic involvement who is infected with an organism that 
is resistant to TMP-SMX or who cannot tolerate this drug. 
Chloramphenicol penetrates well into the brain; amoxicil-
lin-clavulanate does not. Neurologic involvement occurs 
infrequently (1.5% of cases in Thailand; 14), and the chance 
of neurologic disease with a strain that is resistant to TMP-
SMX developing in a patient is low. Use of chlorampheni-
col for postexposure prophylaxis has not been reported, and 
its considerable side effects make it a drug of last choice. 
If this marker were to be allowed, it should never be used 
in a strain resistant to TMP-SMX. Other potential markers 
may encode resistance to members of the ﬂ  uoroquinolone 
group. These drugs have poor activity in vitro (6) and are 
not recommended for the treatment of melioidosis because 
of their poor clinical efﬁ  cacy. A comparison of ciproﬂ  oxa-
cin and azithromycin for 12 weeks versus TMP-SMX and 
doxycycline for 20 weeks demonstrated relapse rates of 
22% and 3%, respectively (15). The relative contribution 
of differences in treatment duration to the rates of relapse 
is not known. However, treatment of 57 adult melioidosis 
patients with ciproﬂ  oxacin or oﬂ  oxacin for a median of 15 
weeks was associated with an unacceptably high failure 
rate of 29% (16). Therefore, because they are clinically of 
little use, we reasoned that some of the recently discovered 
enzyme-mediated ﬂ  uoroquinolone resistance determinants, 
e.g., qnrA and aac(6′)-Ib conferring resistance to ciproﬂ  oxa-
cin and norﬂ  oxacin (17), may be useful for genetic manipu-
lation in Burkholderia spp. However, in exploratory experi-
ments they did not confer sufﬁ  cient levels of norﬂ  oxacin 
resistance to B. thailandensis to be of genetic utility (K.-H. 
Choi and H.P. Schweizer, unpub. data).
International Discrepancies 
In addition to being limited in range, permissible mark-
ers are also subject to considerable international discrepan-
cies in practice and in regulations. For example, although 
TMP-SMX and doxycycline are ﬁ  rst-line drugs for treat-
ment of melioidosis in disease-endemic regions, research-
ers in other parts of the world consistently use trimethop-
rim and tetracycline (which leads to cross-resistance with 
doxycycline) as markers. Use of markers that are prohib-
ited in the United States but not elsewhere leads to several 
problems. First, mutant strains that are resistant to either 
agent cannot be imported to and used in the United States, 
which limits scope for collaborations and sharing of strains. 
Second, US publications describing select agent research 
are monitored, and investigators using nonapproved mark-
ers risk mandated destruction of their mutant collections 
containing such markers. Furthermore, this discrepancy 
encourages US researchers to enlist colleagues abroad to 
advance their research, although such research cannot be ﬁ  -
nanced by NIH. A possible argument for use of trimethop-
rim is that natural resistance is seen at a relatively high fre-
quency (at least in isolates from Thailand), and so its use 
as a marker may be permissible according to the regulatory 
guidelines. Furthermore, handling of these organisms in a 
Biosafety Level 3 facility while wearing protective cloth-
ing limits exposure risk for workers. However, we consider 
it inappropriate to create resistance to an antimicrobial drug 
that is a ﬁ  rst-line treatment for melioidosis and that is the 
agent of choice for postexposure prophylaxis after a labo-
ratory accident in which a worker has had substantial acci-
dental exposure to B. pseudomallei or B. mallei (18).
Conclusions
The list of approved drugs, antimicrobial and nonanti-
microbial, and their respective selection markers is evolv-
ing, but its evolution has not been very transparent because 
no listing of ofﬁ  cially approved drugs and allowed selec-
tion markers is publicly available. Unlike all other bacte-
rial select agents, no approved attenuated strains of B. 
pseudomallei and B. mallei are currently available. Strains 
of select agents can be excluded from the regulations if the 
request is accompanied by data showing that the strain is 
no longer virulent or that the strain is attenuated. Antimi-
crobial drug–resistance markers, including those used in 
human and veterinary medicine, can be introduced into ex-
cluded strains after approval by local institutional biosafety 
committees. To our knowledge, no exclusions had been 
requested of any strain of B. pseudomallei and B. mallei 
at the time of the writing of this article. Recent initiatives 
from the NIH Institute of Allergy and Infectious Diseases 
regarding funding of research for development of nonan-
timicrobial drug–selection markers may alleviate some of 
the problems raised in this article, but not all. Failure to 
address these issues in a timely manner may compromise 
genetic research with B. pseudomallei and B. mallei, cause 
loss of interest by existing researchers, and contribute to 
failure to recruit new persons with expertise into the ﬁ  eld. 
We propose that the international community, regulatory 
authorities, and funding agencies should meet and make 
timely and conclusive decisions to resolve these problems.
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